BK9069 Semiconductors
- 941.174
- -8.030-0.85%
Tesla CEO Elon Musk Says He Feels 'Like A Wince' When Saying 'GPU' As He Boasts Rapid Progress With AI Compute: 'Need A New Word'
Elon Musk, the CEO of Tesla Inc. (NASDAQ:TSLA), has expressed his dissatisfaction with the term GPU while announcing that the company's core AI infrastructure is no longer training-constrained.What Ha
Silo Pharma Shares Are Trading Higher After the Company Announced Intranasal Delivery of SPC-15 Showed a 'Rapid and Effective' Drug Exposure for PTSD Therapy.
Silo Pharma Shares Are Trading Higher After the Company Announced Intranasal Delivery of SPC-15 Showed a 'Rapid and Effective' Drug Exposure for PTSD Therapy.
Rapid AWS Expansion and Increased Cloud Spending Signals Strong Outlook for Amazon: Analyst
Mizuho analyst James Lee reiterated a Buy rating on Amazon.com, Inc (NASDAQ:AMZN) with a price target of $230.Following Lee's latest quarterly survey with a prominent AWS channel partner, he noted sev
Amazon Amps Up Delivery Speed and Trust to Tackle Alibaba Rivals Temu and Shein's Rapid US Expansion
Amazon.Com Inc (NASDAQ:AMZN) is focusing its strategic efforts on countering the rise of emerging e-commerce platforms PDD Holdings Inc (NASDAQ:PDD) Temu and Shein, recognizing them as significant com
Piper Sandler Cuts Inari to Neutral; Cites Slowing Growth, DOJ Probe
Rapid Micro Biosystems: Q4 Earnings Insights
Rapid Micro Biosystems (NASDAQ:RPID) reported its Q4 earnings results on Friday, March 1, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsRapid Micro Biosystems beat
Rapid Micro Expects FY24 Total Revenue Of At Least $27M Vs. $28.29M Estimate, Including The Placement Of At Least 20 Systems
Rapid Micro Expects FY24 Total Revenue Of At Least $27M Vs. $28.29M Estimate, Including The Placement Of At Least 20 Systems
Rapid Micro Biosystems Q4 EPS $(0.26) Beats $(0.30) Estimate, Sales $6.34M Beat $6.15M Estimate
Rapid Micro Biosystems (NASDAQ:RPID) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 33.33 percent increase over losses
BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions
Simulations Plus Extends Collaboration With Translational Toxicology Division At National Institute Of Environmental Health Sciences For Rapid Safety Assessment Of Chemicals In Animals And Humans
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use
RBC Capital Reiterates Outperform on Rapid7, Maintains $70 Price Target
RBC Capital analyst Matthew Hedberg reiterates Rapid7 (NASDAQ:RPD) with a Outperform and maintains $70 price target.
Rapid7 Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/08/2024 27.16% RBC Capital → $70 Reiterates Outperform → Outperform 01/29/2024 27.16% UBS $53 → $70 Upg
PayPal Reports Q4 Results, Joins Rapid7, GoPro And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 10 points on Thursday. Shares of PayPal Holdings, Inc. (NASDAQ:PYPL) fell sharply in today's pre-market tradin
Rapid7 Sees Q1 Adj. EPS $0.52-$0.55 Vs $0.40 Est., Revenue $203M-$205M Vs $204.94M Est.; Sees FY24 Adj. EPS $2.10-$2.21 Vs $1.79 Est., Revenue $848M-$856M Vs $870.23M Est.
Rapid7 Sees Q1 Adj. EPS $0.52-$0.55 Vs $0.40 Est., Revenue $203M-$205M Vs $204.94M Est.; Sees FY24 Adj. EPS $2.10-$2.21 Vs $1.79 Est., Revenue $848M-$856M Vs $870.23M Est.
Rapid7: Q4 Earnings Insights
Rapid7 (NASDAQ:RPD) reported its Q4 earnings results on Wednesday, February 7, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsRapid7 beat estimated earnings by 50.0
Rapid7 Non-GAAP EPS of $0.72 Beats by $0.24, Revenue of $205.27M Beats by $3.92M
Fed's Kugler Says Disinflation Was Rapid In The Second Half Of 2023; Housing Inflation Has Been Persistent But Is Expected To Come Down; Services Ex-Housing Is One Of The Elements To Be Watched For Continued Declines
Fed's Kugler Says Disinflation Was Rapid In The Second Half Of 2023; Housing Inflation Has Been Persistent But Is Expected To Come Down; Services Ex-Housing Is One Of The Elements To Be Watched For Co
Rapid7 Q4 2023 Earnings Preview
UBS Upgrades Rapid7 to Buy, Raises Price Target to $70
UBS analyst Roger Boyd upgrades Rapid7 (NASDAQ:RPD) from Neutral to Buy and raises the price target from $53 to $70.
Needham Starts Inari at Buy, Citing Improving Operating Margins